Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm
- PMID: 33289334
- DOI: 10.1111/cbdd.13812
Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm
Abstract
The present study aimed to assess the repurposing potential of existing antiviral drug candidates (FDA-approved and investigational) against SARS-CoV-2 target proteins that facilitates viral entry and replication into the host body. To evaluate molecular affinities between antiviral drug candidates and SARS-CoV-2 associated target proteins such as spike protein (S) and main protease (Mpro ), a molecular interaction simulation was performed by docking software (MVD) and subsequently the applicability score was calculated by machine learning algorithm. Furthermore, the STITCH algorithm was used to predict the pharmacology network involving multiple pathways of active drug candidate(s). Pharmacophore features of active drug(s) molecule was also determined to predict structure-activity relationship (SAR). The molecular interaction analysis showed that cordycepin has strong binding affinities with S protein (-180) and Mpro proteins (-205) which were relatively highest among other drug candidates used. Interestingly, compounds with low IC50 showed high binding energy. Furthermore, machine learning algorithm also revealed high applicability scores (0.42-0.47) of cordycepin. It is worth mentioning that the pharmacology network depicted the involvement of cordycepin in different pathways associated with bacterial and viral diseases including tuberculosis, hepatitis B, influenza A, viral myocarditis, and herpes simplex infection. The embedded pharmacophore features with cordycepin also suggested strong SAR. Cordycepin's anti-SARS-CoV-2 activity indicated 65% (E-gene) and 42% (N-gene) viral replication inhibition after 48h of treatment. Since, cordycepin has both preclinical and clinical evidences on antiviral activity, in addition the present findings further validate and suggest repurposing potential of cordycepin against COVID-19.
Keywords: 2019nCov; antiviral drugs; cordycepin; coronavirus; drug repurposing.
© 2020 John Wiley & Sons Ltd.
Similar articles
-
Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.Exp Biol Med (Maywood). 2023 Nov;248(21):1927-1936. doi: 10.1177/15353702231209413. Epub 2023 Nov 24. Exp Biol Med (Maywood). 2023. PMID: 37997891 Free PMC article.
-
Cordycepin: a bioactive metabolite of Cordyceps militaris and polyadenylation inhibitor with therapeutic potential against COVID-19.J Biomol Struct Dyn. 2022 May;40(8):3745-3752. doi: 10.1080/07391102.2020.1850352. Epub 2020 Nov 23. J Biomol Struct Dyn. 2022. PMID: 33225826 Free PMC article.
-
Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 Mpro Protease.Molecules. 2020 Nov 6;25(21):5172. doi: 10.3390/molecules25215172. Molecules. 2020. PMID: 33172092 Free PMC article.
-
Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.Top Curr Chem (Cham). 2021 Apr 22;379(3):23. doi: 10.1007/s41061-021-00335-9. Top Curr Chem (Cham). 2021. PMID: 33886017 Free PMC article. Review.
-
An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.Curr Top Med Chem. 2021;21(7):571-596. doi: 10.2174/1568026621666210119111409. Curr Top Med Chem. 2021. PMID: 33463470 Review.
Cited by
-
Niclosamide-Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment.Polymers (Basel). 2021 Mar 26;13(7):1044. doi: 10.3390/polym13071044. Polymers (Basel). 2021. PMID: 33810527 Free PMC article.
-
Impact of BSG/CD147 gene expression on diagnostic, prognostic and therapeutic strategies towards malignant cancers and possible susceptibility to SARS-CoV-2.Mol Biol Rep. 2023 Mar;50(3):2269-2281. doi: 10.1007/s11033-022-08231-1. Epub 2022 Dec 27. Mol Biol Rep. 2023. PMID: 36574092 Free PMC article.
-
Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication.ACS Omega. 2022 Jan 11;7(3):2960-2969. doi: 10.1021/acsomega.1c05998. eCollection 2022 Jan 25. ACS Omega. 2022. PMID: 35071937 Free PMC article.
-
Cordyceps militaris-Fruiting Bodies, Mycelium, and Supplements: Valuable Component of Daily Diet.Antioxidants (Basel). 2022 Sep 21;11(10):1861. doi: 10.3390/antiox11101861. Antioxidants (Basel). 2022. PMID: 36290584 Free PMC article.
-
COVID-19 disease and malignant cancers: The impact for the furin gene expression in susceptibility to SARS-CoV-2.Int J Biol Sci. 2021 Sep 21;17(14):3954-3967. doi: 10.7150/ijbs.63072. eCollection 2021. Int J Biol Sci. 2021. PMID: 34671211 Free PMC article.
References
REFERENCES
-
- Amici, C., Di Coro, A., Ciucci, A., Chiappa, L., Castilletti, C., Martella, V., Decaro, N., Buonavoglia, C., Capobianchi, M. R., & Santoro, M. G. (2006). Indomethacin has a potent antiviral activity against SARS coronavirus. Antiviral Therapy, 11(8), 1021-1030.
-
- Andersen, P. I., Ianevski, A., Lysvand, H., Vitkauskiene, A., Oksenych, V., Bjoras, M., Telling, K., Lutsar, I., Dampis, U., Irie, Y., & Tenson, T. (2020). Discovery and development of safe-in-man broad-spectrum antiviral agents. International Journal of Infectious Diseases, 93, 268-276. https://doi.org/10.1016/j.ijid.2020.02.018
-
- Bleasel, M. D., & Peterson, G. M. (2020). Emetine, ipecac, ipecac alkaloids and analogues as potential antiviral agents for coronaviruses. Pharmaceuticals, 13(3), 1-9. https://doi.org/10.3390/ph13030051
-
- Buyya, R., Branson, K., Giddy, J., & Abramson, D. (2003). The Virtual Laboratory: A toolset to enable distributed molecular modelling for drug design on the World-Wide Grid. Concurrency and Computation: Practice and Experience, 15(1), 1-25. https://doi.org/10.1002/cpe.704
-
- Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 1-4.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous